"To Boldly Go Where No One Has Gone Before: Neoadjuvant Strategies in N" by Chee Yao Lim, Mohmed Imran Gora et al.
 

To Boldly Go Where No One Has Gone Before: Neoadjuvant Strategies in NSCLC

Document Type

Article

Publication Date

10-2024

Publication Title

Chest Journal

Abstract

Non-small cell lung cancer (NSCLC), two-thirds of which present with metastatic disease, significantly burdens the healthcare system. It has been established that surgical curative intent can be attempted on patients with single oligometastatic disease (M1b), which has a favorable outcome, especially when there is no mediastinal involvement. The AEGEAN trial suggested that patients with stages II to IIIB resectable NSCLC be treated with neoadjuvant chemotherapy before surgery, followed by adjuvant durvalumab, which significantly extends event-free survival. Our cases explore the possible role of neoadjuvant approach in select NSCLC patients described below who underwent curative surgery.

Volume

166

Issue

4 Supplement

First Page

A4310

Last Page

A4311

DOI

10.1016/j.chest.2024.06.2615

This document is currently not available here.

Find in My Library

Share

COinS